Fulgent Genetics, Inc.
HealthcareNASDAQ:FLGT · NASDAQ Global Market
-$0.10 today
Vol 0.22M · Avg 0.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.4%
avg -10.8%
ROIC
-7.1%
avg -4.5%
ROA
-5.0%
avg -9.8%
Analysis
ROA is currently the strongest return metric at -5.0% versus its period average of -9.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ming Hsieh | Chairman & Chief Executive Officer | $2.21M | — | 70 | $897,685.00 | 3.16% |
Paul Kim | Chief Financial Officer | $973,352.00 | — | 59 | $364,632.00 | 1.28% |
Jian Xie | Chief Operating Officer & President | $962,658.00 | — | 60 | $369,751.00 | 1.30% |
Hanlin Gao FACMG | Chief Scientific Officer & Laboratory Director | $813,249.00 | — | 59 | $992,062.00 | 3.49% |
Ray Yin | President & Chief Scientific Officer of Fulgent Pharma | — | — | — | — | — |
Natalie Prescott | General Counsel & Chief Privacy Officer | — | — | — | — | — |
Brandon Perthuis | Chief Commercial Officer | — | — | — | — | — |
Elias Nyankojo | Chief Information Security Officer | — | — | — | — | — |
Jakub Sram | Vice President of Business Development & Sales | — | — | — | — | — |
Doreen Ng | Vice President of Operations & Compliance | — | — | — | — | — |
Ellen Tsui | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$612,899.72
Net Sentiment
$612,899.72
Net selling
Most Active
Xie Jian
8 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $612,899.72 over the last 12 months. That adds up to net selling of $612,899.72. Xie Jian was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +30.7% | +35.2% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +30.7% over three years. Forward estimates point to Revenue at +35.2% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
CareDx, Inc
NASDAQ:CDNA
$1.19B
Personalis, Inc.
NASDAQ:PSNL
$851.63M
Castle Biosciences, Inc.
NASDAQ:CSTL
$627.83M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Myriad Genetics, Inc.
NASDAQ:MYGN
$408.96M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
Anavex Life Sciences Corp.
NASDAQ:AVXL
$231.68M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
Who manages FLGT?
Fulgent Genetics, Inc. (FLGT) lists 11 active executives. The top listed executive is Hanlin Gao FACMG, Chief Scientific Officer & Laboratory Director.
Are FLGT insiders buying or selling?
Recent insider activity shows net selling of $7.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.